Completed

Genetic Studies in Alzheimer's Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Alzheimer's Disease

+ Nervous System Disease
How is the trial designed

Other

Observational
Study Start: February 1988

Summary

Principal SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner
Study start date: February 1, 1988Actual date on which the first participant was enrolled.

Alzheimer's disease is a condition marked by the deterioration of mental function. The disease usually begins in late middle life and results in death in 5 to 10 years. Patients with Alzheimer's disease typically suffer from memory loss, confusion, and disorientation. The condition has become a major medical and social problem in the United States because of the increasing number of people living beyond the age of 65. The actual cause of Alzheimer's disease is unknown. Researchers believe that Alzheimer's disease, or at least a portion of cases, may be an inherited condition. As a result, many new techniques have been developed to study the genetic causes of Alzheimer's disease and other neurological disorders. Many of these genetic techniques require blood samples and a family pedigree. A pedigree is a chart, similar to a family tree, that shows a patient's family history. The purpose of this study is to collect family and psychosocial information, blood, and biopsy samples from patients with neurological diseases, their families, and normal volunteers. This information gathered will be used to learn more about diseases that affect the brain. This is a screening and follow-up Protocol. Recent technological advances have facilitated the development of new approaches for investigating the underlying genetic basis of neurological disorders, but genetic questions remain open and on going. Application of many genetic techniques require a family pedigree and blood sample. Peripheral blood lymphoblasts which are banked also serve as a renewable source for harvesting DNA which can be used for developing genetic markers in the future. This study will allow collection of family and psychosocial information and blood specimens from patients with neurological diseases, their families, and normal control subjects.

Official TitleBiochemical and Genetic Studies in Familial Alzheimer's Disease 
Principal SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
1500 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
Healthy volunteers allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Alzheimer's Disease
Nervous System Disease
Criteria
No eligibility criteria are available at this time.Please check with the study contact for more details. 
Anonymus Profile Image
Ensure optimum compatibilityAdd your profile to know your probability eligibility score.


Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 1 location
Suspended
National Institute of Neurological Disorders and Stroke (NINDS)Bethesda, United StatesSee the location

CompletedOne Study Center